A Clinically Translatable Immune-based Classification of HPV-associated Head and Neck Cancer with Implications for Biomarker-Driven Treatment Deintensification and Immunotherapy
Zeng, P. Y.; Cecchini, M. J.; Barrett, J. W.; Shammas-Toma, M.; De Cecco, L.; Serafini, M. S.; Cavalieri, S.; Licitra, L.; Hoebers, F.; Brakenhoff, R. H.; Leemans, C. R.; Scheckenbach, K.; Poli, T.; Wang, X. Y.; Liu, X.; Laxague, F.; Prisman, E.; Poh, C.; Bose, P.; Dort, J.; Shaikh, M. H.; Belle Ryan, S. E. E.; Dawson, A.; Khan, M. I.; Howlett, C. J.; Stecho, W.; Plantinga, P.; da Silva, S. D.; Hier, M.; Khan, H.; MacNeil, D.; Mendez, A.; Yoo, J.; Fung, K.; Lang, P.; Winquist, E.; Palma, D.; Ziai, H.; Amelio, A. L.; Li, S.; Boutros, P. C.; Mymryk, J. S.; Nichols, A. C.
Show abstract
PurposeHuman papillomavirus-associated (HPV+) head and neck squamous cell carcinoma (HNSCC) is the fastest rising cancer in North America. There is significant interest in treatment de-escalation for these patients given the generally favourable prognosis. However, 15-30% of patients recur after primary treatment, reflecting a need for improved risk-stratification tools. We sought to develop a molecular test to predict the survival of patients with newly diagnosed HPV+ HNSCC. MethodsWe created a prognostic score (UWO3) that was successfully validated in six independent cohorts comprising 906 patients, including blinded retrospective and prospective external validations. Transcriptomic data from two aggressive radiation de-escalation cohorts were used to assess the ability of UWO3 to identify patients who recur. Multivariate Cox models were used to assess the associations between the UWO3 immune class and outcomes. ResultsA three-gene immune score classified patients into three immune classes (immune rich, mixed, or immune desert) and was strongly associated with disease-free survival in six datasets, including large retrospective and prospective datasets. Pooled analysis demonstrated that the immune rich group had superior disease-free survival at 5 years to the immune desert (HR= 9.0, 95% CI 3.2-25.5, P=3.6x10-5) and mixed (HR=6.4, 95%CI 2.2-18.7, P=0.006) groups after adjusting for age, sex, smoking status, and AJCC8 clinical stage. Finally, UWO3 was able to identify patients from two treatment de-escalation cohorts who remain disease-free after aggressive de-escalation to 30 Gy radiation. ConclusionsThe UWO3 immune score could enable biomarker-driven clinical decision-making for patients with HPV+ HNSCC based on robust outcome prediction across six independent cohorts. The superior survival of immune rich patients supports de-intensification strategies, while the inferior outcomes of the immune desert patients suggest the potential for intensification and/or immunotherapy. Prospective de-escalation and intensification clinical trials are currently being planned.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response 95%
- Multiplexed RNA-FISH-guided Laser Capture Microdissection RNA Sequencing Improves Breast Cancer Molecular Subtyping, Prognostic Classification, and Predicts Response to Antibody Drug Conjugates 95%
- A single cell atlas reveals distinct immune landscapes in transplant and primary tumors that determine response or resistance to immunotherapy 95%
Similar papers in this journal
- Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumour immunity 94%
- Cancer-associated fibroblast compositions change with breast cancer progression linking S100A4 and PDPN ratios with clinical outcome 94%
- Cell lineage as a predictor of immune response in neuroblastoma 93%
Similar papers in this journal
- Tumor-localized interleukin-2 and interleukin-12 combine with radiation therapy to safely potentiate regression of advanced malignant melanoma in pet dogs 95%
- Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors 94%
- Non-invasive multi-cancer detection using DNA hypomethylation of LINE-1 retrotransposons 93%
Similar papers in this journal
- Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies 94%
- Single-cell integration and multi-modal profiling reveals phenotypes and spatial organization of neutrophils in colorectal cancer 94%
- Evolutionary states and trajectories characterized by distinct pathways stratify ovarian high-grade serous carcinoma patients 93%
Similar papers in this journal
- Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy 95%
- Deep immune profiling reveals targetable mechanisms of immune evasion in checkpoint blockade-refractory glioblastoma 95%
- Intratumor Childhood Vaccine-Specific CD4+ T cell Recall Coordinates Antitumor CD8+ T cells and Eosinophils 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.